



# Texas Node Newsletter

Winter 2012, Issue: 1

## Trivedi's Thoughts

### Inside this Issue:

<b>Node Highlights</b>	<b>2</b>
<b>Protocol Pipeline</b>	<b>3</b>
<b>Protocols in Progress</b>	<b>3-4</b>
<b>CTP Scoop</b>	<b>5-6</b>
<b>Bridging the Gap</b>	<b>6-8</b>
<b>Training</b>	<b>8</b>
<b>Recent Publications</b>	<b>8</b>
<b>Upcoming Events</b>	<b>9</b>

A belated Happy New Year to you all!

Due to your continued commitment to our Texas Node, we have made solid advances in all key performance areas since August 2010. We expanded RRTC management adjuncts in both San Antonio and Houston and extended participation in CTN protocols to sites in both of these locations. We implemented the first CTN funded protocol led by our Node. We are currently conducting more studies simultaneously than ever before. We are submitting study concepts to NIDA. This has resulted in us implementing the first genetics protocol conducted within the CTN in the form of an ancillary study related to the CURB protocol. We have also significantly increased our publication activities. This year promises to be a productive year for our Node as we continue to evaluate and modify the organization, management, and direction.



One of our goals is to establish additional means of communicating to all Texas Node members to ensure everyone remains informed throughout the year. You will continue to receive periodic emails with information about upcoming opportunities and the CTN Bulletin. We are currently developing a Texas Node website. This will increase our web presence and it will become a primary method of communicating information. The other method is through this newsletter that will be distributed quarterly to all Node members. The goal of the newsletter is to provide overviews and updates of the Node's current studies, publications, dissemination activities, and other items of potential interest to you all. We welcome your input and contributions to the newsletter.

The upcoming year provides us the opportunity to continue growing and strengthening the Node's reputation and presence within the CTN. We have already been selected to participate in two upcoming protocols. Parkland Hospital will be making their first CTN appearance as a CTP for CTN-0049 Project HOPE, and Nexus Recovery Center will be implementing their fourth CTN protocol, CTN-0052 BRAC, later this year. In April the Texas Node will host its first dissemination conference in Dallas.

*(Continued on Page 2)*

## Newsletter Challenge

I challenge **YOU**,  
Texas Node  
colleagues!


While the name "Texas Node Newsletter" clearly states what the document is, we can all agree we're not going to win any journalism awards for best titled newsletter. We need a title that is concurrently creative, representative and memorable. Send your ideas to [Aubrey.Hopkins@utsouthwestern.edu](mailto:Aubrey.Hopkins@utsouthwestern.edu) and we'll present what can only be the much-improved, permanent name and its brilliant creator in the next issue.

(Continued from page 1)

As this is the first issue of our newsletter, the following pages review our recent past and what's in store for our future. In the next issue we hope to use feedback and updates from you to form a newsletter that reaches out to all Texas Node members.

Because of you, our scholars, practitioners, and researchers, who daily draw upon your own passions to fuel your dedication, I am confident we will successfully navigate the upcoming years and continue to create a stronger, more accomplished organization.

Regards,



## Node Highlights

### 2012 Texas Research to Practice Conference



On Monday, April 30, 2012, we will be holding the **2012 Texas Research to Practice Conference**. This event will take place from 8am to 5pm at UT Southwestern Medical Center in Dallas. Madhukar Trivedi, M.D. will begin the conference with an introduction of the conference and its guest speakers. Speakers will then present current research, followed by lunch, additional speaker seminars, and final words from Dr. Trivedi. Presenters will address evidence based practices with a focus on the provider's role in community-based treatment.

*Presentations will include:*

**Exercise and Addiction**, Madhukar Trivedi, M.D.

**HIV Blending Product**, Richard Spence, Ph.D.

**Conducting Research in a Community Based Setting: Challenges and Rewards**, A. Rebecca Crowell, M.Ed., LPC, LCDC; Douglas Denton, M.A., LCDC, LCCA

**Pharmacotherapies in Substance Use Disorders Treatment**, Thomas Kosten, M.D.

**CTN-0030 Prescription Opioid Addiction Treatment Study (POATS) Blending Product**, Jennifer S. Potter, Ph.D., M.P.H.

**Seeking Safety**, Denise Hien, Ph.D.

**Motivational Interviewing**, Mary M. Velasquez, Ph.D.

**Research into Practice - Motivational Incentives**, Michael Levy, Ph.D.

**Brief Strategic Family Therapy**, José Szapocznik, Ph.D.

The conference provides attendees with an opportunity to identify and evaluate new trends, therapies, and techniques in community-based treatment and to network with professional colleagues.

*~Contributed by Kristen Rosen, M.P.H.*

For more information contact Jeanne McCurdy at 214-648-4384 or [Jeanne.McCurdy@utsouthwestern.edu](mailto:Jeanne.McCurdy@utsouthwestern.edu).

# Texas Protocol Pipeline



## CTN-0049 Project HOPE (Hospital Visit as Opportunity for Prevention and Engagement) for HIV-Infected Drug Users

**Parkland** and nine other sites were chosen by the Lead Team at the Florida Node Alliance after submitting a survey, having a phone interview, and then a site visit by the selection committee. Project Hope will evaluate the effectiveness of a brief intervention delivered to HIV-infected drug users recruited from the hospital setting in achieving viral suppression. In addition, the study will try to determine the effects of the intervention on linkage to and retention in HIV primary care, linkage to and retention in drug abuse treatment, and reduction in numbers of hospitalizations. National protocol training is scheduled for the first week in April with recruitment projected to start in May.



## CTN-0052 A Randomized Controlled Evaluation of Buspirone for Relapse-Prevention in Adults with Cocaine Dependence (BRAC)

Congratulations go to **Nexus Recovery Center**, as they have now been selected to implement their fourth CTN study! The BRAC study's main objective is to evaluate the efficacy of buspirone, relative to placebo, in preventing relapse in cocaine-dependent adults in inpatient/residential treatment who are planning to enter outpatient treatment upon discharge. The Lead Team at the Ohio Valley Node recently announced the six sites selected for this protocol and scheduled the national protocol training for June 25<sup>th</sup> and 26<sup>th</sup>. BRAC is slated to begin recruiting August 1<sup>st</sup>.



## CTN-0048-A-1 CURB Genetics Protocol

The CURB Genetics protocol is the **first ancillary study led by our Node** and it is also the first **genetics study for the CTN!** The Protocol Co-PIs are Drs. David Nielsen and Tom Kosten from the Baylor College of Medicine in Houston. The CURB Genetics Study's primary aim is to determine what role genes play in the effectiveness of buprenorphine and naltrexone (BUP/NTX) as a potential treatment for cocaine dependence. Participants will be recruited from individuals enrolled in CTN-0048 CURB. If a relationship is found between an individual's genetic makeup and his response to BUP/NTX, it could lead to revisions to improve current treatment models for cocaine dependence. The 11 CURB sites are currently preparing their local IRB submissions so they can begin recruiting for CURB Genetics!

## Protocols in Progress



## CTN-0037 Stimulant Reduction Intervention using Dosed Exercise (STRIDE)

As you all know, STRIDE is the first CTN study we at the Texas Node are leading. The trial will determine if adding exercise to treatment as usual decreases substance use in people with either stimulant abuse or dependence. It continues to be an exciting and challenging study, one that we're meeting head-on. Given the challenges of retaining participants throughout this nine month study, we enlisted the help of STRIDE study consultant Dr. Tim Church and his staff who invited the STRIDE Exercise Facilitators to a training workshop held in November at the Pennington Biomedical Research Institute in Baton Rouge, Louisiana. The Exercise Facilitators were presented with a wealth of participant recruitment and selection methods and techniques to strengthen retention rates in long-term studies.

(Continued on page 4)

(Continued from page 3)

The Exercise Facilitators returned home recharged, inspired and excited to share their knowledge with their STRIDE team members. The **video recordings from these two days at Pennington are highly recommended to all research teams**, not just STRIDE. The recordings have been uploaded to LiveLink and are located in the Training folder within the CTN-0037 Protocol Project folder.

Recruitment for the STRIDE trial has exceeded two-thirds of the goal of 330 participants with **Nexus** claiming the position of recruiting the most participants study-wide (they have recruited 118% of their target recruitment to date).

**Memorial Hermann** is also one of the top recruiting sites (96% of target recruitment to date). **Keep it up Texas sites!**



### CTN-0044 Web-Delivery of Evidence-Based, Psychosocial Treatment for Substance Use Disorders

Led by the Long Island Regional Node, CTN-0044 is being conducted locally at **Homeward Bound**. The primary objective of this study is to evaluate the effectiveness of including an interactive, web-based version of the Community Reinforcement Approach intervention plus incentives targeting drug abstinence and treatment participation. The intervention is designed to replace a small part of community-based, outpatient substance abuse treatment and is being evaluated against treatment as usual. *Homeward Bound recruited 55 participants, making it the second top recruiting site for the entire study!* There are currently six papers in process using baseline data and our research team is working on a paper on counselors' perspectives on the intervention.



### CTN-0046 Smoking Cessation and Stimulant Treatment (S-CAST)

The S-CAST study is evaluating the impact of concurrent outpatient smoking session and stimulant treatment on stimulant dependence. The study recently exceeded the target sample size by enrolling their 528th participant on December 2, 2011.

Sites are currently in the follow-up phase. **Nexus** was the first Wave 2 site to meet the recruitment goal and *is among the top recruitment leaders of the trial with an overall rate of 112%*.

The Nexus site has also been acknowledged for meeting Lead Team recruitment and retention goals for the past 6 months in a row. **Congratulations to the S-CAST Nexus team for your superb recruitment and retention performance throughout the trial!**

### CTN-0048 Cocaine Use Reduction with Buprenorphine (CURB)



CURB is the latest study in our Node to begin recruiting participants! As of January 24<sup>th</sup>, 67 clients have been enrolled into the trial. The aim of this study is to investigate the safety and effectiveness of buprenorphine in the presence of naltrexone for the treatment of cocaine dependence in individuals meeting diagnostic criteria for both cocaine dependence and either past year opioid dependence, past-year opioid abuse, or past-year opioid use with a history of opioid dependence during their lifetime. Congratulations to the CTN staff at the **South Texas Veterans Health Care System** (the Audie L. Murphy VA Hospital in San Antonio) for being chosen to participate in their first CTN study. *As a result, the Texas Node has now actively expanded to San Antonio!*



This section will contain updates from each Texas Node CTP. To have your CTP included in the next issue, please send information to [Aubrey.Hopkins@utsouthwestern.edu](mailto:Aubrey.Hopkins@utsouthwestern.edu)



### Memorial Hermann Prevention & Recovery Center (PaRC) Receives President's Cup

One of our Houston sites and the 10<sup>th</sup> largest non-profit healthcare system in the nation, recently received the 2011 President's Cup for Overall Outstanding Performance in Non-Acute Care Services at the Memorial Hermann Annual Meeting. The President's Cup is the highest award given annually by Memorial Hermann President and CEO Dan Wolterman. The award highlights a unit or division's success within the Memorial Hermann Healthcare System. In order to be considered for this award, the unit or department must excel in all six system strategies employed by Memorial Hermann to drive its efforts and help the system to fulfill its mission: Quality, Patients (Satisfaction), Physicians (Satisfaction), People (Employee Satisfaction & Engagement), Operational Excellence, and Growth. PaRC received this acknowledgement in 2006 and 2008, making the 2011 award the third time PaRC has received this recognition.

### PaRC STRIDE Team's Sexy Snowman Raises Money through Holiday Tin Project

To celebrate the holidays during December, Memorial Hermann Prevention and Recovery Center's (PaRC) Partners in Caring team once again had their Holiday Tin Project to raise money for the Partners in Caring Employee Fund. This fund was implemented in April 1991 to assist fellow employees experiencing a crisis or catastrophe resulting in a

*"The snowman was built using 55cm and 65cm stability balls, six jump ropes, two forearm trainers, a health bow, two water bottles, 30 lottery tickets and of course, a lot of Stride gum." ~Gabe Fuzat*

financial emergency. Memorial Hermann employees who have worked for the system for at least one year and are experiencing a crisis

that has created an urgent need for financial assistance are eligible to apply to the fund. Each year PaRC's departments demonstrate their creativity and generosity by creating a uniquely decorated holiday tin that is displayed during the holiday season and then auctioned off to the highest bidder.

The PaRC STRIDE team was determined to make an impression by using their innovative abilities during the Holiday Tin Project. The facilitators **Gabriel Fuzat** and **Paige Harris** and the RAs, **Lora Bunge** and **Amber Thomas-Gordon** created a large snowman "walking" on a treadmill. The snowman was built using 55cm and 65cm stability balls, six jump ropes, two forearm trainers, a health bow, two water bottles, 30 lottery tickets and of course, a lot of Stride gum. "There were so many professional looking tins," one Holiday Tin Project attendee noted, "The STRIDE tin was just so . . . in your face and creative." Just as some pets resemble their owners, the STRIDE tin undeniably embodied the persona of the PaRC STRIDE Team.

In all, 12 departments contributed a holiday tin to this year's auction raising almost \$650 for the Partners in Caring Employee Fund. The STRIDE tin was auctioned off at over \$80, the second largest amount paid for a tin!

*~Contributed by Gabe Fuzat*



### Nexus Awarded \$1.5 Million for Project FORWARD

The Substance Abuse and Mental Health Services Administration (SAMHSA) awarded Nexus Recovery Center, Inc. a three-year, \$1.5 million grant to serve high-risk pregnant or post-partum women who have co-occurring mental health and substance use disorders.

The aptly named Project FORWARD (Family-Oriented Resources for Women Accessing Recovery in Dallas) will serve 40 adult women annually, along with their dependent children up to 17 years of age.

"We actually started Nexus' program for pregnant women with SAMHSA funding back in 1993. The program has really evolved since then, and this funding provides validation of that," stated Executive Director Becca Crowell. "We're excited that the grant includes funding for formal, outside project evaluation by a research psychologist. Plus, we are trying to diversify, so it's great to regain this long dormant funding source."

Project FORWARD clients will receive 90 days of intensive residential treatment on a special unit for pregnant women. The project will serve women living in the Dallas Metroplex area who are 18 years of age or older, their children up to 17 years of age, and their families. The majority of clients will be referred through Dallas County Specialty Courts or Dallas County Child Protective Services due to behaviors that put them and their children at high risk, resulting in intervention by the justice or child protection systems.

**Congratulations Nexus!**

~Contributed by Raman Sandhu

## Bridging the Gap




### Primary Findings of CTN-0030 Prescription Opioid Addiction Treatment Study (POATS)

POATS was the first large-scale clinical trial to examine prescription opioid addiction treatment; recently the primary outcomes from the study were published in the *Archives of General Psychiatry*. There were two treatment phases in this trial. During Phase 1, participants first went through two weeks of buprenorphine-naloxone treatment, followed by a 2-week taper period, and finally a two month follow-up period. At the end of Phase 1, only those participants who were not effectively treated for their opioid addiction entered Phase 2, which consisted of a three month buprenorphine-naloxone treatment, one month taper period, and two month follow-up. All participants in both phases received buprenorphine-naloxone and were randomized to either standard medical management (SMM) or SMM plus opioid dependency counseling. The results indicate buprenorphine-naloxone is an effective treatment for patients with prescription opioid addiction but that once buprenorphine-naloxone is removed from their treatment plan, relapse rates greatly increase.

Almost 50% of participants decreased their prescription opioid use during the 12-week buprenorphine-naloxone intervention. When the buprenorphine-naloxone treatment was discontinued, the participants' abstinence rate plummeted to 8.6%. These results beg additional research to further reveal the true worth of detox in the presently accepted treatment model for prescription opioid abuse.

**Dr. Jennifer Potter**, the San Antonio RRTC PI, was the National Project Director for POATS when she was with the New England Consortium. She also co-authored the primary outcome paper, "[Adjunctive Counseling During Brief and Extended Buprenorphine-Naloxone Treatment for Prescription Opioid Dependence: A 2-Phase Randomized Controlled Trial](#)" by Roger D. Weiss, MD; Jennifer Sharpe Potter, PhD; et al. and is continuing to analyze data from this high-impact trial.



### Effects of Tanning: Adinoff and colleagues discover similar brain activity in tanning bed users & addicts

The study by **Bryon Adinoff, M.D.** on the effect of tanning on the brain has received much attention and it is the first study to examine brain activity inside a tanning bed. Cynthia Harrington, M.D., a former dermatology resident at UT Southwestern, approached Dr. Adinoff with a desire to study a recurring problem she had observed in her clinical practice: patients refusing to stop tanning even after suffering significant skin damage. Drs. Harrington, Adinoff, and other colleagues designed a study to explore this phenomenon that appeared potentially addictive.

They recruited participants from tanning salons who tanned at least three times a week and assessed brain blood flow during two different tanning sessions. On one of the occasions the participants received a normal tanning session where they were exposed to UV light and for the other session the participants were deprived of UV light without their knowledge. During tanning sessions where UV light was present, the parts of the brain associated with reward and addiction were activated. During sessions where UV light was removed, these areas were significantly less active. These findings were supported by participants' self-reports assessed before and after the sessions. Participants receiving the normal session had a decreased desire to tan after their session compared to before their session.

Participants receiving the sham session had desire to tan ratings that remained just as elevated as they were before their session. "What this shows is that the brain is in fact responding to UV light, and it responds in areas that are associated with reward," said Dr. Adinoff. "These are areas, particularly the striatum, that we see activated when someone is administered a drug or a high-value food like sugar."

*~From The New York Times article "How Tanning Changes the Brain"*

Stimulant  
Abuser Groups  
(STAGE-12)



CTN  
0031

### Preliminary Results from CTN-0031 STAGE-12 (Stimulant Abuser Groups to Engage in 12-Step): Evaluation of a Combined Individual-Group Intervention to Reduce Stimulant and Other Drug Use by Increasing 12-Step Involvement

CTN-0031 STAGE-12 was the very first CTN study implemented by **Nexus Recovery Center**. In fact, Nexus and two other sites were chosen specifically due to their inexperience conducting CTN research. The Lead Team has been vocal about how well those research naïve sites performed throughout the study as compared to the other sites that implemented the study. Since a significant number of patients fail to become engaged in 12-step programs during their treatment, STAGE-12 was created to provide clinicians with the skills to encourage initial and maintained attendance in 12-step programs. The study evaluated the effectiveness of the group-plus-individually delivered 12-step facilitative intervention (STAGE-12), integrated into outpatient treatment as usual (TAU), as a treatment for people with stimulant use disorders by comparing it to outpatient TAU. The lead investigators are still sorting through the various results from this study, but here are some of the initial findings. Overall, STAGE-12 increases the probability of being abstinent from stimulants during and in the last 30 days of the active treatment phase. However, if abstinence is not achieved during this period, rates of stimulant use appear to actually be greater among STAGE-12 participants. STAGE-12 was associated with greater attendance at 12-step meetings. **Sam Hilliard, M.P.A., L.C.D.C**, **Sunne Hogan, L.P.C.**, and **DeRisa Payne, L.C.D.C.** led the STAGE-12 intervention at Nexus and even implemented portions of STAGE-12 treatment into their own curriculum after the study concluded. The Lead Team is still sorting out exactly what these findings mean for treatment and publications of these findings are being worked on.



## Are you Genetics Savvy?

NIH recently launched the first internet-based genetics training specifically geared for educating social and behavioral scientists—and it's completely free!

This training will give you a better idea of how the addition of a genetics perspective can enhance your future investigation endeavors and help you understand the role genetics play in behavior.

[www.nchpeg.org/bssr](http://www.nchpeg.org/bssr)

Check out **ISAJE's PARINT** website for information and resources on writing and editing addiction journal articles!



The CCC's 2012 Webinar Catalog is now online!

To browse the catalog & register for upcoming webinars visit the CTN

[Dissemination Library Training Page.](#)

**Webinars are for counselors and researchers!**



## CTN-0031-A An Evaluation of Neurocognitive Function, Oxidative Damage, and Their Association with Treatment Outcomes in Methamphetamine and Cocaine Abusers

CTN-0031-A was an ancillary study to CTN-0031, meaning only CTN-0031 participants could participate. The primary aim of this ancillary study was to replicate previous findings that neurocognitive deficits on the Stroop color-word interference task is correlated with completion of substance use disorder treatment in stimulant users. Oxidative damage in cocaine and methamphetamine users was measured, via blood sample, to determine if oxidative stress plays a primary role in the neurocognitive deficits associated with stimulant use. The results of the Stroop task did not replicate those found by other research groups. In addition, oxidative damage did not play a primary role in the neurocognitive deficits. More analyses are under way to determine what else can be learned from this study.



## Recent Publications

Svikis, D.S., Keyser-Marcus, L., Stitzer, M., Rieckmann, T., Safford, L., Loeb, P., Allen, T., Luna-Anderson, C., Back, S.E., Cohen, J., DeBernardi, M.A., Dillard, B., Forcehimes, A., Jaffee, W., Killeen, T., Kolodner, K., Levy, M., Pallas, D., Perl, H.L., **Sharpe Potter, J.**, Provost, S., Reese, K., Sampson, R.R., Sepulveda, A., Snead, N., Wong, C.J., Zweben, J. Randomized multi-site trial of the Job Seekers' Workshop in patients with substance use disorders. *Drug and Alcohol Dependence*, 120: 55-64, 2012.

Bogenschutz, M., Donovan, **Adinoff, B.H.**, Crandall, C., Forcehimes, A., Lindblad, R., Mandler, R.N., Oden, N., Perl, H.I., **Walker, R.** Design of NIDA CTN protocol 0047: Screening, brief motivational assessment, referral, and treatment in emergency departments (SMART-ED). *American Journal of Drug and Alcohol Abuse*, 37: 417-425, 2011.

**Chartier, K.G.**, Hesselbrock, M.N., & Hesselbrock, V.M. Alcohol problems in young adults transitioning from adolescence to adulthood: The association with race and gender. *Addictive Behaviors*, 36(3): 167-174, 2011. PMID: 3018558

Dodrill, C., Helmer, D., **Kosten, T.R.** Treatments in psychiatry: Prescription pain medication dependence. *American Journal of Psychiatry*, 158(5): 466-471, 2011.

Oden, N.L., Van Veldhuisen, P.C., Wakim, P., **Trivedi, M.H.**, Somoza, E., Lewis, D. Power of automated algorithms for combining Time Line Follow Back and urine drug screening test results in stimulant-abuse clinical trials. *American Journal of Drug and Alcohol Abuse*, 37: 350-357, 2011.

Subramaniam, G.A., **Warden, D.**, **Minhajuddin, A.**, Fishman, M.J., Stitzer, M.L., **Adinoff, B.H.**, **Trivedi, M.H.**, Weiss, R., **Potter, J.S.**, Poole, S.A., Woody, G.E. Predictors of abstinence: NIDA multi-site buprenorphine/naloxone treatment trial in opioid dependent youth. *Journal of the American Academy of Child and Adolescent Psychiatry*, 50: 1120-1128, 2011.

Campbell, A.N.C., Nunes, E.V., Miele, G.M., Matthews, A., Polsky, D., Ghitza, U.E., Turrigiano, E., Bailey, G.L., VanVeldhuisen, P., Chapdelaine, R., Froias, A., Stitzer, M.L., Carroll, K.M., Winhusen, T., Clingerman, S., Perez, L., McClure, E., Goldman, B., **Crowell, A.R.** Design and methodological considerations of an effectiveness trial of a computer-assisted intervention: An example from the NIDA Clinical Trials Network. *Contemporary Clinical Trials*, 33: 386-395, 2012.

**Trivedi, M.H.**, **Greer, T.L.**, **Potter, J.S.**, **Grannemann, B.D.**, Nunes, E.V., **Rethorst, C.**, **Warden, D.**, **Ring, K.M.**, Somoza, E. Determining the primary endpoint for a stimulant abuse trial: Lessons learned from STRIDE (CTN 0037). *American Journal of Drug and Alcohol Abuse*, 37, 339-349, 2011, doi: 10.3109/00952990.2011.598589.

(Continued on page 9)



Oliveto, A., Poling, J., Mancino, M.J., Feldman, Z., Cubells, J.F., Pruzinsky, R., Gonsai, K., Car-  
 gile, C., Sofuoglu, M., Chopra, M.P., Gonzalez-Haddad, G., Carroll, K.M., **Kosten, T.R.** Random-  
 ized, double blind, placebo-controlled trial of disulfiram for the treatment of cocaine dependence  
 in methadone-stabilized patients. *Drug and Alcohol Dependence*, 113: 184-191, 2011. PMID:  
 3005977.

Shorter, D., **Kosten, T.R.** Vaccines in the treatment of substance abuse. *Focus*. 9(1):25-30,  
 2011.

**Mark Your  
 Calendars!**



**April 2<sup>nd</sup>-5<sup>th</sup>**

**CTN-0049 National  
 Training  
 Miami, FL**

**April 17<sup>th</sup>-18<sup>th</sup>**

**CTN Steering  
 Committee Meeting  
 Atlanta, GA**

**April 19<sup>th</sup>**

**Mini-Blending  
 Meeting  
 Atlanta, GA**

**April 19<sup>th</sup>-22<sup>nd</sup>**

**American Society of  
 Addiction Medicine  
 Conference  
 Atlanta, GA**

**April 30<sup>th</sup>**

**Texas Research to  
 Practice Conference  
 Dallas, TX**

**May 5<sup>th</sup>-9<sup>th</sup>**

**American Psychiatric  
 Association  
 Philadelphia, PA**

**May 19<sup>th</sup>-22<sup>nd</sup>**

**National Association of  
 Addiction Treatment  
 Providers  
 Phoenix, AZ**

**June 25<sup>th</sup>-26<sup>th</sup>**

**CTN-0052 National  
 Training**

**Texas Node Word Search**

Y L X Q F J D G I G I L Y X B H N F R L O P N B D W N V X O  
 D R X L X I Y N Y C Z J U J V Y N V E V L E P O A A S V S G  
 G V E B N S T I P D L J Q O U I U E T C Q O R M M N K K P  
 X S D V S X A K R X A Y M A O B F Y T T P S C W B G F C I A  
 C X X N I C N O P L W B R B L F X Q E R E Q O O T Y T X V H  
 E C E A A L M M C D H A R Z G V J T L A T N O B T P I D Y H  
 T Y S T J G E S O D S T N C M U P M S I S Q V O S O X V Z X  
 N G H C K Y P D Q M Q Z J D J R S C W N A T U C X L R B Q U  
 Y F E I W I R J B Y L L R G A S K W E I D V O S Z R D P O P  
 N R Y N V E B X E E O U E F Z G Q Z N N A O E T L M Q T G A  
 B L P B E C B I F R W C J H B B M M H G P H D R E K Y O A D  
 F N E Y Z T U I P Y N M F F D D S A X E T N O I M T Z C M R  
 Y N Q E P I I J N E C C H I Y M S P M Y G N N D N S N C W X  
 N N P U U D R C R A E G B J N D X C I Y D I X E L B X R E B  
 O B J U J P V E S I R U I J A M Z I Q M T C H V C C K N F Q  
 N I S O P N F V A X P V S K U H A Q B Z R R G N Y K M W Z L  
 J P B O C N G R E R D Y N A Q I U I S P T A N N I N G N N V  
 X I B W O U Y Q E E Z E U K K S S C H A L L E N G E E T B H  
 Q R N C N R P N U O B D G J M P W R F N F Q O D N X C I R L  
 A A J E K H O H C R A E S E R M I V Q C T U D N U A S O A O  
 H O D C K R H B H F A L N N I H F F E B B G P S J R I M T  
 W Y G T P G B M Q A T I J I P X W N I H C Q K U O N J J S P  
 Q G D H J O A L Y R S V V C H Q C N K F R B I E W N C R G A  
 A C I S P J Y W L H Y M Y E O K I V K Q K K K R O I R A C I  
 E N C O E C F T D Y A P Z N A K H N K M V Y C S H D D X D X  
 E H P Y V R B U A E Q Z X M B Y L T P M O N E O H O Q B M H  
 N O I T A N I M E S S I D T A S D U Q I K S M P T C V T I Q  
 X X C A V B D K K Q A M L W J O E B Y Q R R W T O V Y Z R I  
 R P X Z C J N J I R W R S Y A Q T I A Y T R E G A H O S L J  
 A U X D N H S R F O X N T A W A M K F V S A U A P J Y D Q Y

- WORD LIST:**
- BUPRENORPHINE
  - CHALLENGE
  - CONFERENCE
  - CTN
  - CTP SCOOP
  - DISSEMINATION
  - GENETICS
  - HOPE
  - NEWSLETTER
  - NEXUS
  - NODE
  - PROTOCOL
  - RESEARCH
  - SMOKING
  - SNOWMAN
  - STRIDE
  - TANNING
  - TEXAS
  - TRAINING
  - WEB DELIVERY
  - WEBINAR

**Send updates for  
 future issues and any  
 newsletter related questions to**

**[Aubrey.Hopkins@utsouthwestern.edu](mailto:Aubrey.Hopkins@utsouthwestern.edu)**

**A special thank you to Maleeha Akhtar for all of her help!**